You are here

Publications

Found 7 results
Author Title Type [ Year(Asc)]
Filters: Author is Rock, Jeremy M  [Clear All Filters]
2026
Schnappinger D, Berthel SJ, Boshoff HIM, Krieger IV, Sukheja P, Panda S, Rath S, Briggs K, Bian X, Rasheed S et al..  2026.  Integrating chemical, genetic, and feasibility assessments for anti-tubercular target validation.. EMBO Mol Med.
Theriault ME, Wong AI, DeJesus MA, Pisu D, Lee BNae Rin, Kirukubar G, Li S, Wallach JB, Schnappinger D, Lê-Bury G et al..  2026.  Utilization of a CRISPRi-based ex vivo challenge model to reveal temporally dependent gene essentiality in intracellular Mycobacterium tuberculosis.. mBio. :e0061026.
2025
Jinich A, Zaveri A, DeJesus MA, Spencer A, Almada-Monter R, Flores-Bautista E, Smith CM, Sassetti CM, Rock JM, Ehrt S et al..  2025.  The Mycobacterium tuberculosis Transposon Sequencing Database (MtbTnDB): A Large-Scale Guide to Genetic Conditional Essentiality.. Mol Microbiol. 124(1):91-101.
2024
Bosch B, DeJesus MA, Schnappinger D, Rock JM.  2024.  Weak links: Advancing target-based drug discovery by identifying the most vulnerable targets.. Ann N Y Acad Sci. 1535(1):10-19.
2022
Li S, Poulton NC, Chang JS, Azadian ZA, DeJesus MA, Ruecker N, Zimmerman MD, Eckartt KA, Bosch B, Engelhart CA et al..  2022.  CRISPRi chemical genetics and comparative genomics identify genes mediating drug potency in Mycobacterium tuberculosis.. Nat Microbiol. 7(6):766-779.
2021
Bosch B, DeJesus MA, Poulton NC, Zhang W, Engelhart CA, Zaveri A, Lavalette S, Ruecker N, Trujillo C, Wallach JB et al..  2021.  Genome-wide gene expression tuning reveals diverse vulnerabilities of M. tuberculosis.. Cell. 184(17):4579-4592.e24.
2017
Rock JM, Hopkins FF, Chavez A, Diallo M, Chase MR, Gerrick ER, Pritchard JR, Church GM, Rubin EJ, Sassetti CM et al..  2017.  Programmable transcriptional repression in mycobacteria using an orthogonal CRISPR interference platform.. Nat Microbiol. 2:16274.